Tag Archives: pricing

Pricing Management: It's All About the Data

By James Robinson. Any pricing or revenue management initiative is only as good as the information on which it is based. However, too many pharma companies continue to adopt a fragmented, siloed data approach which fails to make the most of this critical business asset.
Posted in Europe, Guest Blog, pricing | Also tagged , , | Leave a comment

NICE's Tarceva Decision "Perverse", Says Roche

The UK National Institute for Health and Care Excellence’s (NICE) decision that relapsed non-small cell lung cancer patients should no longer have access to Roche’s cancer pill Tarceva (erlotinib) is a setback for lung cancer care in England and Wales, where “over 1,000 patients a year will be left without an active treatment option after […]
Posted in pricing, Regulatory | Also tagged , , , , | Leave a comment

Who's Watching the Drug Watchdogs?

It is nowadays fashionable to question everyone in authority, and there is no shortage of self-appointed watchdogs who aim to make sure that things that happen are happening as they should. The drug industry and drug regulatory authorities have been among the most conspicuous targets of this intense monitoring, on everything from questionable payments to […]
Posted in Europe, Global, Guest Blog, Op-Ed, Regulatory | Also tagged , , , , | 1 Comment

UK: Is Value Based Assessment the New Value Based Pricing?

NICE and Value Based Assessment: An Update By Leela Barham VBA is the new VBP The initial proposals for Value Based Pricing (VBP) have evolved into something very different.  Now there is focus on Value Based Assessment (VBA), which is really focusing on adding just two factors to the usual methods of assessing new medicines: […]
Posted in Europe, Global, Guest Blog, pricing | Also tagged , , , , , | Leave a comment

England: Is the Cancer Drugs Fund Running Out of Money?

By Leela Barham. The headlines have moved on for the English Cancer Drugs Fund (CDF). Replacing the positive press releases such as “thousands of patients to benefit” in 2013 are headlines shouting out that “thousands face being denied life-extending medication”.  In other words, a return to the same concerns that prompted the creation of the […]
Posted in Europe, Global, Guest Blog, pricing, Regulatory | Also tagged , , , | 1 Comment
  • Categories

  • Meta